INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 168 filers reported holding INTELLIA THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $316,200 | -22.5% | 10,000 | 0.0% | 2.69% | +20.6% |
| Q2 2023 | $407,800 | +9.4% | 10,000 | 0.0% | 2.23% | +27.5% |
| Q1 2023 | $372,700 | +6.8% | 10,000 | 0.0% | 1.75% | +0.8% |
| Q4 2022 | $348,900 | -37.7% | 10,000 | 0.0% | 1.74% | +4.6% |
| Q3 2022 | $560,000 | +8.1% | 10,000 | 0.0% | 1.66% | +41.0% |
| Q2 2022 | $518,000 | -28.7% | 10,000 | 0.0% | 1.18% | +75.9% |
| Q1 2022 | $727,000 | -38.5% | 10,000 | 0.0% | 0.67% | +29.7% |
| Q4 2021 | $1,182,000 | -11.9% | 10,000 | 0.0% | 0.52% | +15.7% |
| Q3 2021 | $1,342,000 | -17.1% | 10,000 | 0.0% | 0.45% | +56.5% |
| Q2 2021 | $1,618,000 | -98.2% | 10,000 | -99.1% | 0.28% | -98.1% |
| Q1 2021 | $89,359,000 | +1.7% | 1,113,376 | -31.1% | 15.01% | +7.8% |
| Q4 2020 | $87,873,000 | +173.6% | 1,615,321 | 0.0% | 13.93% | -58.1% |
| Q3 2020 | $32,113,000 | -5.4% | 1,615,321 | 0.0% | 33.22% | -8.5% |
| Q2 2020 | $33,954,000 | +71.9% | 1,615,321 | 0.0% | 36.31% | -13.1% |
| Q1 2020 | $19,756,000 | -16.6% | 1,615,321 | 0.0% | 41.77% | +1.2% |
| Q4 2019 | $23,697,000 | +9.9% | 1,615,321 | 0.0% | 41.29% | +16.3% |
| Q3 2019 | $21,564,000 | -18.5% | 1,615,321 | 0.0% | 35.49% | +25.5% |
| Q2 2019 | $26,443,000 | -4.2% | 1,615,321 | 0.0% | 28.28% | +9.1% |
| Q1 2019 | $27,590,000 | +25.1% | 1,615,321 | 0.0% | 25.92% | +2.1% |
| Q4 2018 | $22,049,000 | -52.3% | 1,615,321 | 0.0% | 25.39% | +3.8% |
| Q3 2018 | $46,230,000 | -8.0% | 1,615,321 | -12.1% | 24.47% | +10.6% |
| Q2 2018 | $50,255,000 | +4.5% | 1,836,810 | -19.4% | 22.12% | -39.1% |
| Q1 2018 | $48,081,000 | -30.1% | 2,279,788 | -36.3% | 36.34% | -40.4% |
| Q4 2017 | $68,804,000 | -22.7% | 3,579,788 | 0.0% | 60.94% | -3.0% |
| Q3 2017 | $88,958,000 | +49.1% | 3,579,788 | -4.0% | 62.83% | -34.4% |
| Q2 2017 | $59,677,000 | +13.6% | 3,729,788 | 0.0% | 95.72% | -4.3% |
| Q1 2017 | $52,553,000 | -9.5% | 3,729,788 | -15.8% | 100.00% | 0.0% |
| Q4 2016 | $58,075,000 | – | 4,429,788 | – | 100.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 572,950 | $19,990,226 | 5.79% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $39,952,225 | 5.34% |
| MPM BioImpact LLC | 455,238 | $15,883,254 | 4.12% |
| ARK Investment Management | 9,420,782 | $328,691,084 | 2.85% |
| Atlas Venture Associates IX, LLC | 10,000 | $348,900 | 1.74% |
| Ghisallo Capital Management LLC | 250,000 | $8,722,500 | 1.55% |
| Nikko Asset Management Americas, Inc. | 2,976,002 | $103,743,430 | 1.49% |
| Prosight Management, LP | 72,116 | $2,516,127 | 1.37% |
| Rokos Capital Management LLP | 826,063 | $28,391,785 | 1.24% |
| Elmwood Wealth Management, Inc. | 67,899 | $2,368,996 | 1.18% |